Komori
Alfresa Holdings (2784) · FactFirst stated

FY2022-Q2 Lower Revenue and Profit in the Wholesale Business for Prescription Pharmaceuticals and Other Products

First written in FY2022-Q2. . Latest entry: FY2022-Q2.

1entries
1years
0from disclosures
Share on X
How it moved
Same theme, other companies
医療用医薬品等卸売事業の薬価改定・価格交渉等による減収減益A theme 1 companies write about · 1 as a headwind · 0 as a tailwind

No other company in this theme has enough history to compare yet.

Full recordFilings, disclosures and news, newest first
  1. FY2022-Q2First statedAnnual report

    「当セグメントの当第２四半期連結累計期間の業績は、このような状況のなか、売上高1兆1,333億50百万円（前年同期は1兆1,393億21百万円）、営業利益70億31百万円（同96億39百万円）となりました。」

    医療用医薬品等卸売事業は、感染拡大、中間年薬価改定、価格交渉および入札指名停止等の影響があるなか、前年同期比で減収減益となった。
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
No upcoming earnings preview for Alfresa Holdings yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.